Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Biomaterials. 2013 Jan 29;34(12):2980–2990. doi: 10.1016/j.biomaterials.2013.01.046

Fig. 3.

Fig. 3

Doxorubicin-incorporated triple-shell nanoparticles enhance nanoparticle uptake into cancer cells in vitro. (a–b) Unbound caveolin-1 levels and nanoparticle uptake are enhanced in H292 cells following a 0.5 or 4 h incubation with doxorubicin-incorporated nanoparticles (NP-DOX-Dy550). Bars represent means ± s.e.m. (n ≥ 25 cells, *p < 0.05 for NP-DOX-Dy550 compared to NP-siCTRL-Dy550 using Student’s t test). (b) Representative confocal micrographs of H292 cells after a 4 h treatment with NP-siCTRL-Dy550 or NP-DOX-Dy550 and corresponding free caveolin-1 expression. (c) Representative immuno-EM photomicrographs of unbound caveolin-1 levels in H292 cells following a 4 h treatment with NP-siXIAP-Dy550 or NP-DOX-siXIAP-Dy550. 15 nm gold-conjugated secondary antibodies, black arrows. Scale bars, 500 nm.